Document Type
Article
Publication Date
2-12-2018
JAX Source
Nat Commun 2018 Feb 12; 9(1):621
Volume
9
Issue
1
First Page
621
Last Page
621
ISSN
2041-1723
PMID
29434196
DOI
https://doi.org/10.1038/s41467-018-03061-x
Abstract
Albumin and IgG have remarkably long serum half-lives due to pH-dependent FcRn-mediated cellular recycling that rescues both ligands from intracellular degradation. Furthermore, increase in half-lives of IgG and albumin-based therapeutics has the potential to improve their efficacies, but there is a great need for robust methods for screening of relative FcRn-dependent recycling ability. Here, we report on a novel human endothelial cell-based recycling assay (HERA) that can be used for such pre-clinical screening. In HERA, rescue from degradation depends on FcRn, and engineered ligands are recycled in a manner that correlates with their half-lives in human FcRn transgenic mice. Thus, HERA is a novel cellular assay that can be used to predict how FcRn-binding proteins are rescued from intracellular degradation. Nat Commun 2018 Feb 12; 9(1):621.
Recommended Citation
Grevys A,
Nilsen J,
Sand K,
Daba M,
Øynebråten I,
Bern M,
McAdam M,
Foss S,
Schlothauer T,
Michaelsen T,
Christianson GJ,
Roopenian DC,
Blumberg R,
Sandlie I,
Andersen J.
A human endothelial cell-based recycling assay for screening of FcRn targeted molecules. Nat Commun 2018 Feb 12; 9(1):621
Comments
Open access under Creative Commons Attribution (CC BY) license (Creative Commons Attribution 4.0 International License).